Khosla backs Neurotrack in $6.5M as it launches web-based, eye-tracking cognitive test

Palo Alto, CA's Neurotrack launched its first product, the Imprint, a digital cognitive assessment test for the evaluation of patients who may be at risk for cognitive decline. The goal is to advance research and treatment of cognitive diseases like Alzheimer's. In addition, the company reported $6.5 million in new funding, led by Khosla Ventures and supported by Social Capital, Founders Fund, AME Cloud Ventures and iSeed Ventures. The web-based test takes 5 minutes and utilizes eye-tracking technology to assess recognition memory and hippocampal impairment. Release

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.